Navigation Links
SCOLR Pharma, Inc. Appoints Stephen J. Turner as CEO

BOTHELL, Wash., Aug. 31 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (NYSE Amex: DDD) announced the appointment of Stephen J. Turner as Chief Executive Officer and President as of August 31, 2009. The employment of Dr. Bruce S. Morra in these positions terminated on August 28 by mutual agreement. Dr. Morra will continue to serve as a director of the Company.

Mr. Turner has been Vice President and Chief Technical Officer of SCOLR since 2003 and has been instrumental in development of SCOLR's proprietary Controlled Delivery Technology (CDT(R)). Mr. Turner said "SCOLR plans to continue efforts to license our 12 hour 600 mg ibuprofen formulation and we are advancing discussions with potential partners. In addition, we are making progress on our program to gain approval for our extended release pseudoephedrine. In the short term, we will direct efforts to increase distribution and sales of our nutraceutical products both in the area of providing new products and expanding into new areas."

Michael Taglich, Chairman of the Board, said, "Steve Turner is a natural leader and I am confident we will succeed with him at the helm. He has tremendous knowledge of the drug delivery and formulation business and has the right combination of skills to take this company to the next level. I also want to thank Bruce Morra for stepping in when he did. Bruce has helped guide us in advancing discussions with a number of potential partners that could significantly enhance shareholder value. We look forward to Bruce's continued presence as a member of the Board going forward."

About SCOLR Pharma:

Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company. SCOLR Pharma's corporate objective is to combine its formulation expertise and its patented CDT platform to develop novel pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425.368.1050 or visit

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, including activities, events or developments that we expect, believe or anticipate will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including our ability to advance development of our potential products and complete research and development, our ability to raise additional funds or enter strategic alliances, the continuation of arrangements with our product development partners and customers, competition, government regulation and approvals, and general economic conditions.. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.

    Stephen Turner
    SCOLR Pharma, Inc.
    (425) 368-1050 ext. 1080

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. SCOLR Pharma, Inc. Submits Abbreviated New Drug Application for a 12-hour CDT-based Pseudoephedrine Formulation
2. SCOLR Pharma, Inc. Schedules Third Quarter 2008 Financial Results Conference Call for November 7, 2008 at 11:30 A.M. Eastern
3. SCOLR Pharma, Inc. Announces Positive Top-Line Results From Pivotal Clinical Trial Evaluating Efficacy of Extended-Release Ibuprofen
4. SCOLR Pharma, Inc. Announces Resignation of CEO Daniel O. Wilds
5. SCOLR Pharma, Inc. Announces Appointment of Bruce S. Morra, Ph.D., as President & CEO
6. SCOLR Pharma, Inc. Schedules Fourth Quarter 2008 Financial Results Conference Call for March 11, 2009 at 11:30 A.M. Eastern
7. SCOLR Pharma, Inc. Announces Engagement of HealthPro as Financial Advisor
8. SCOLR Pharma, Inc. Schedules First Quarter 2009 Financial Results Conference Call for May 1, 2009 at 11:30 A.M. Eastern
9. SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results
10. GeoPharma, Inc. to Present at the EdgeWater Research Investor Conference
11. TyRx Pharma, Inc. Announces Presentation of Results to Benefit Women with Breast Implants (In-Vivo Efficacy Study Regarding AIGISRx DEB) at the Plastic Surgery 2007 Meeting on October, 28 2007 in Baltimore, MD
Post Your Comments:
(Date:10/13/2015)... Nashville, Tennessee (PRWEB) , ... October 13, 2015 ... ... owned leader of anesthesia and pain management services, today announced its partnership with ... the partnership integrates data from disparate systems and organizes the data into an ...
(Date:10/13/2015)... ... October 13, 2015 , ... ProText Kinetic Panel is ... With ProText Kinetic Panel, users can create energetic text animations in any layout without ... the Final Cut Pro X timeline and stylize the text. With intuitive on-screen controls, ...
(Date:10/13/2015)... ... October 13, 2015 , ... Element ... products, introduced a new company, RightSensor™ LLC, an Internet of Things (IoT) hardware ... RightSensor™ provides a fully-managed approach for customers requiring sensor hardware for critical data ...
(Date:10/13/2015)... CA (PRWEB) , ... October 13, 2015 , ... Dr. ... by Medical New Today on September 18, 2015. The research, which was conducted at ... Dr. Wael Sabbah and colleagues, show connections between stress during pregnancy and future dental ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... A child ... that’s why SmileCareClub , the leading remote invisible aligner system, has joined with ... would otherwise go without it. For each aligner treatment plan purchased, SmileCareClub will donate ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... , Oct. 13, 2015  Mylan N.V. (Nasdaq: ... 5:00 p.m. ET host a conference call and webcast to ... plc (NYSE: PRGO ; TASE) shareholders through Mylan,s offer ... Mylan,s Executive Chairman Robert J. Coury , CEO ... --> --> Mylan will ...
(Date:10/13/2015)... -- Synapse Biomedical Inc. ( ) reported today that ... use of the NeuRx ® Diaphragm Pacing System ... the United States and patient ... PAS study group met their initial enrollment goal ahead ... expanded the enrollment target to 150 participants.   ...
(Date:10/13/2015)... COLLEGE PARK, Md. , Oct. 13, 2015 ... hubs is the biggest key to growing Baltimore ... to a report released today by the Maryland Technology ... already has many of the pieces in place to support ... Martha Connolly , director of Mtech Baltimore. "This study is ...
Breaking Medicine Technology: